from memory i think that endpoints need to be specific (not a combination of things) and that non-inflammatory lesions were chosen as secondary endpoint (not primary) because there they are hard to treat and there was less expectation of improvements compared to the inflammatory lesions.
Ann: Cowen Conference and Additional BTX 1503 Data Analysis, page-20
-
- There are more pages in this discussion • 46 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add BOT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
34.3¢ |
Change
0.023(7.03%) |
Mkt cap ! $627.0M | |||
| Open | High | Low | Value | Volume |
| 33.5¢ | 34.8¢ | 33.5¢ | $1.658M | 4.890M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 8 | 121970 | 34.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 34.5¢ | 467576 | 10 |
View Market Depth
| Last trade - 11.58am 14/11/2024 (20 minute delay) ? |
| BOT (ASX) Chart |